Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

1.

Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.

Jackson TL, Dugel PU, Bebchuk JD, Smith KR, Petrarca R, Slakter JS, Jaffe GJ, Nau JA; CABERNET Study Group.

Ophthalmology. 2013 Aug;120(8):1597-603. doi: 10.1016/j.ophtha.2013.01.074. Epub 2013 Mar 13.

PMID:
23490325
[PubMed - indexed for MEDLINE]
2.

Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).

Dugel PU, Bebchuk JD, Nau J, Reichel E, Singer M, Barak A, Binder S, Jackson TL; CABERNET Study Group.

Ophthalmology. 2013 Feb;120(2):317-27. doi: 10.1016/j.ophtha.2012.07.068. Epub 2012 Nov 20.

PMID:
23174399
[PubMed - indexed for MEDLINE]
3.

Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography.

Petrarca R, Dugel PU, Nau J, Slakter JS, Jaffe GJ, Jackson TL.

Ophthalmology. 2013 Feb;120(2):328-33. doi: 10.1016/j.ophtha.2012.07.091. Epub 2012 Nov 22.

PMID:
23178157
[PubMed - indexed for MEDLINE]
4.

Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.

Dugel PU, Petrarca R, Bennett M, Barak A, Weinberger D, Nau J, Jackson TL.

Ophthalmology. 2012 Jul;119(7):1425-31. doi: 10.1016/j.ophtha.2012.01.014. Epub 2012 Mar 30.

PMID:
22465819
[PubMed - indexed for MEDLINE]
5.

Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.

Jackson TL, Chakravarthy U, Kaiser PK, Slakter JS, Jan E, Bandello F, O'Shaughnessy D, Gertner ME, Danielson L, Moshfeghi DM; INTREPID Study Group.

Ophthalmology. 2013 Sep;120(9):1893-900. doi: 10.1016/j.ophtha.2013.02.016. Epub 2013 Mar 13.

PMID:
23490327
[PubMed - indexed for MEDLINE]
6.

Safety testing of epimacular brachytherapy with microperimetry and indocyanine green angiography: 12-month results.

Petrarca R, Richardson M, Douiri A, Nau J, McHugh D, Stangos AN, Jackson TL.

Retina. 2013 Jun;33(6):1232-40. doi: 10.1097/IAE.0b013e3182794b22.

PMID:
23508075
[PubMed - indexed for MEDLINE]
7.

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2013 Jan;120(1):122-9. doi: 10.1016/j.ophtha.2012.07.042. Epub 2012 Oct 6.

PMID:
23047002
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Avila MP, Farah ME, Santos A, Carla L, Fuji G, Rossi J, Nau J.

Retina. 2012 Jan;32(1):10-8. doi: 10.1097/IAE.0b013e31822528fc.

PMID:
21817963
[PubMed - indexed for MEDLINE]
9.

Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration.

Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S.

Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):453-8. doi: 10.1007/s00417-012-2038-0. Epub 2012 May 11.

PMID:
22573410
[PubMed - indexed for MEDLINE]
10.

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group.

Ophthalmology. 2013 May;120(5):1046-56. doi: 10.1016/j.ophtha.2012.10.014. Epub 2013 Jan 23.

PMID:
23352196
[PubMed - indexed for MEDLINE]
Free Article
11.

Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.

Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM.

Ophthalmology. 2014 Jun;121(6):1237-45. doi: 10.1016/j.ophtha.2013.12.029. Epub 2014 Mar 28.

PMID:
24684838
[PubMed - indexed for MEDLINE]
12.

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).

Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group.

Ophthalmology. 2013 Nov;120(11):2292-9. doi: 10.1016/j.ophtha.2013.03.046. Epub 2013 May 3.

PMID:
23642856
[PubMed - indexed for MEDLINE]
13.

Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.

Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S.

Ophthalmology. 2012 Aug;119(8):1621-7. doi: 10.1016/j.ophtha.2012.02.022. Epub 2012 May 1.

PMID:
22551738
[PubMed - indexed for MEDLINE]
14.

Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.

Bloch SB, Lund-Andersen H, Sander B, Larsen M.

Am J Ophthalmol. 2013 Jul;156(1):116-124.e1. doi: 10.1016/j.ajo.2013.02.012. Epub 2013 May 8.

PMID:
23664150
[PubMed - indexed for MEDLINE]
15.

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.

Brown DM, Chen E, Mariani A, Major JC Jr; SAVE Study Group.

Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.

PMID:
23131717
[PubMed - indexed for MEDLINE]
16.

The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.

Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group.

Ophthalmology. 2014 May;121(5):1092-101. doi: 10.1016/j.ophtha.2013.11.031. Epub 2014 Jan 23.

PMID:
24461586
[PubMed - indexed for MEDLINE]
Free Article
17.

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.

Spielberg L, Leys A.

Graefes Arch Clin Exp Ophthalmol. 2010 Jul;248(7):943-56. doi: 10.1007/s00417-009-1256-6. Epub 2010 Mar 4.

PMID:
20204659
[PubMed - indexed for MEDLINE]
18.

Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.

Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study Group.

Ophthalmology. 2007 Oct;114(10):1868-75. Epub 2007 Jul 12.

PMID:
17628683
[PubMed - indexed for MEDLINE]
19.

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group.

Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.

PMID:
23916488
[PubMed - indexed for MEDLINE]
20.

Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration.

Hörster R, Ristau T, Sadda SR, Liakopoulos S.

Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):645-52. doi: 10.1007/s00417-010-1588-2. Epub 2010 Dec 18.

PMID:
21170547
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk